AbbVie deal adds to pharma scramble

Merger boom fuelled by need to boost pipelines

AbbVie wins three-way Pharmacyclics fight

Value of healthcare deals in past 15 months reaches nearly $500bn

Vertex climbs on drug approval hopes

US stocks edge higher after two days of declines

DUGGAN...Robert W. Duggan, CEO of Californian-based Computer Motion, gestures during a news conference in Paris Wednesday Sept.19, 2001. A French surgeon in New York performed a gall bladder operation this month on a patient in France, a first-of-its-kind procedure made possible by advances in high-speed telecommunications. Computer Motion is the company that developed the robots used in the surgery. (AP Photo/Francois Mori)

Pharmacyclics CEO sees stake value soar

Venture capitalist came to pharma industry via tragedy

Centerview builds record on pharma deals

Investment bank builds on consumer products role

Imbruvica capsules by Pharmacyclis

AbbVie/Pharmacyclics: pay to play

Big Pharma’s cost of doing business is rising. So are share prices. Can this go on?

Philips’s wind-up foetal heart rate monitor

GE and Philips scan Africa medical market

Diagnostic equipment makers seek multimillion-dollar contracts

Imbruvica capsules by Pharmacyclis

Q&A: why AbbVie had to buy Pharmacyclics

The $21bn dramatic deal that raised stakes in sector M&A spree

AbbVie in $21bn swoop on Pharmacyclics

Company trumps J&J to acquire US cancer drugmaker

AbbVie acquires Pharmacyclics in $21bn deal

Company unexpectedly trumps rival US suitor Johnson & Johnson

Case study: Kiran Mazumdar-Shaw, founder of Biocon

The taste of success for an entrepreneur in male-dominated industry

Merck predicts flat earnings for 2015

Net income down amid switch from pharma to speciality chemicals and lab supplies

Hikma set to join pharma blue-chips

Jordanian drugmaker outgrows Mideast roots

Unnerving history of the head transplant

Moral concerns are as great a barrier as surgical problems

GSK-Novartis deal ‘a model’ for industry

Pharma groups bet heavy on ‘precision M&A’

UK drug manufacture drops by a quarter

Blow to coalition ambition to promote high-growth industry

Tullow faces blue-chip relegation

Hikma Pharma ready to grab spot in the top tier

Chi-Med poised for China drug milestone

Cancer treatments set to be filed for regulatory approval in 2016

Outlook improves for European companies

Deflation a concern while ability to push up prices ‘limited’

Nikon buys Optos for £259m

Japanese group diversifying into medical technology


More FT Twitter accounts